Dermatology Kinerase® Oxsoralen-Ultra® United States

Home Why EFUDEX®? Indications How EFUDEX® Works Treatment FAQ / What to Expect Other Products Links References For Additional Information Call: United States 1.800.556.1937 Rapid Clearance of AKs Efficacy is achieved in as little as 2 weeks1 Cures up to 86% of visible AK lesions in just 2-4 weeks1 Additional AK lesions were also detected and resolved during treatment6,7 Benefits of EFUDEX® Starts working within the first week of treatment8 Provides rapid resolution of AK lesions6,7 Offers excellent cosmetic outcome7 Solar of Actinic Keratoses (AK) may Develop into Squamous Cell Carcinoma2 AKs represent the earliest stages of squamous cell carcinoma (SCC)2 Since the 1960's, the incidence of SCC has been increasing 4% to 8% per year9 Squamous cell skin cancer affects about 100,000 Americans each year9 2,000 to 2,500 Americans die each year due to SCC of the skin2 Patients may have up to 10 times as many subclinical/undetected lesions for each visible AK10 Younger patients are developing AKs3 Proven Efficacy in sBCC(5% Strength)1 The Cure Rate for EFUDEX® is consistently high 93% cure rate in sBCC1 At least 3-6 weeks, and up to 10-12 weeks sBCC treatment duration EFUDEX® offers benefits when conventional methods are impractical Minimizes the risk of hypopigmentation11 Provides an effective option for large and difficult to treat areas11 Treats surrounding AK lesions1 sBCC is among the most common types of skin cancer BCC makes up about 80% of all skin cancers9 An increased incidence of sBCC in younger patients may be due to greater sun exposure3 sBCCs represent approximately 15% of BCCs12 Trust the experience of EFUDEX® in both sBCCs and AKs Over 30 years of proven clinical experience8 Over 14 million prescriptions since 19725 EFUDEX® is the #1 prescribed topical 5-FU13 Important Safety Information EFUDEX® is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant. The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, rash, scaling, scarring, photosensitivity, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. Printer Friendly Prescribing Information Over 14 million prescriptions have been written for Efudex over last 30 years5 High success rates

IMPORTANT SAFETY INFORMATION EFUDEX® (fluorouracil) Topical Solutions and Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. EFUDEX is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant. The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, scaling, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. Please see complete Prescribing Information for EFUDEX. © Valeant Pharmaceuticals International 2005  Legal and Privacy Statement Efudex® is a registered trademark of Valeant Pharmaceuticals International